Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients

Ryohei Kawabata; Hisashi Wada; Midori Isobe; Takashi Saika; Shuichiro Sato; Akiko Uenaka; Hiroshi Miyata; Takushi Yasuda; Yuichiro Doki; Yuji Noguchi; Hiromi Kumon; Kazuhide Tsuji; Keiji Iwatsuki; Hiroshi Shiku; Gerd Ritter; Roger Murphy; Eric Hoffman; Lloyd J. Old; Morito Monden; Eiichi Nakayama

doi:10.1002/ijc.22583

Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients

Ryohei Kawabata, Hisashi Wada, Midori Isobe, Takashi Saika, Shuichiro Sato, Akiko Uenaka, Hiroshi Miyata, Takushi Yasuda, Yuichiro Doki, Yuji Noguchi, Hiromi Kumon, Kazuhide Tsuji, Keiji Iwatsuki, Hiroshi Shiku, Gerd Ritter, Roger Murphy, Eric Hoffman, Lloyd J. Old, Morito Monden, Eiichi Nakayama

Graduate School of Medicine Dentistry and Pharmaceutical Sciences

Research output: Contribution to journal › Article

55 Citations (Scopus)

Abstract

NY-ESO-1 specific humoral responses are frequently observed in patients with various types of NY-ESO-1 antigen expressing tumors. In a large proportion of NY-ESO-1 antibody-positive patients of NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring of the NY-ESO-1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY-ESO-1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY-ESO-1 protein formulated with cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) and investigated the humoral immune responses against NY-ESO-1. Seven patients were NY-ESO-1 antibody-negative and 2 patients were positive prior to vaccination. Vaccination with CHP-NY-ESO-1 resulted in the induction or increase of NY-ESO-1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY-ESO-1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY-ESO-1 antibody-positive cancer patients. A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients. In conclusion, we showed that CHP-NY-ESO-1 protein vaccination had a potent activity for inducing humoral immune responses against NY-ESO-1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1.

Original language	English
Pages (from-to)	2178-2184
Number of pages	7
Journal	International Journal of Cancer
Volume	120
Issue number	10
DOIs	https://doi.org/10.1002/ijc.22583
Publication status	Published - May 15 2007

Keywords

Antibody response
CHP
Cancer vaccine
NY-ESO-1

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/ijc.22583

Fingerprint Dive into the research topics of 'Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients'. Together they form a unique fingerprint.

Cite this

Kawabata, R., Wada, H., Isobe, M., Saika, T., Sato, S., Uenaka, A., Miyata, H., Yasuda, T., Doki, Y., Noguchi, Y., Kumon, H., Tsuji, K., Iwatsuki, K., Shiku, H., Ritter, G., Murphy, R., Hoffman, E., Old, L. J., Monden, M., & Nakayama, E. (2007). Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. International Journal of Cancer, 120(10), 2178-2184. https://doi.org/10.1002/ijc.22583

Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. / Kawabata, Ryohei; Wada, Hisashi; Isobe, Midori; Saika, Takashi; Sato, Shuichiro; Uenaka, Akiko; Miyata, Hiroshi; Yasuda, Takushi; Doki, Yuichiro; Noguchi, Yuji; Kumon, Hiromi; Tsuji, Kazuhide; Iwatsuki, Keiji; Shiku, Hiroshi; Ritter, Gerd; Murphy, Roger; Hoffman, Eric; Old, Lloyd J.; Monden, Morito; Nakayama, Eiichi.

In: International Journal of Cancer, Vol. 120, No. 10, 15.05.2007, p. 2178-2184.

Research output: Contribution to journal › Article

Kawabata, R, Wada, H, Isobe, M, Saika, T, Sato, S, Uenaka, A, Miyata, H, Yasuda, T, Doki, Y, Noguchi, Y, Kumon, H, Tsuji, K, Iwatsuki, K, Shiku, H, Ritter, G, Murphy, R, Hoffman, E, Old, LJ, Monden, M & Nakayama, E 2007, 'Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients', International Journal of Cancer, vol. 120, no. 10, pp. 2178-2184. https://doi.org/10.1002/ijc.22583

Kawabata, Ryohei ; Wada, Hisashi ; Isobe, Midori ; Saika, Takashi ; Sato, Shuichiro ; Uenaka, Akiko ; Miyata, Hiroshi ; Yasuda, Takushi ; Doki, Yuichiro ; Noguchi, Yuji ; Kumon, Hiromi ; Tsuji, Kazuhide ; Iwatsuki, Keiji ; Shiku, Hiroshi ; Ritter, Gerd ; Murphy, Roger ; Hoffman, Eric ; Old, Lloyd J. ; Monden, Morito ; Nakayama, Eiichi. / Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. In: International Journal of Cancer. 2007 ; Vol. 120, No. 10. pp. 2178-2184.

@article{d319060c1ce947e382dd9cd5cbc6bd66,

title = "Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients",

abstract = "NY-ESO-1 specific humoral responses are frequently observed in patients with various types of NY-ESO-1 antigen expressing tumors. In a large proportion of NY-ESO-1 antibody-positive patients of NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring of the NY-ESO-1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY-ESO-1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY-ESO-1 protein formulated with cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) and investigated the humoral immune responses against NY-ESO-1. Seven patients were NY-ESO-1 antibody-negative and 2 patients were positive prior to vaccination. Vaccination with CHP-NY-ESO-1 resulted in the induction or increase of NY-ESO-1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY-ESO-1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY-ESO-1 antibody-positive cancer patients. A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients. In conclusion, we showed that CHP-NY-ESO-1 protein vaccination had a potent activity for inducing humoral immune responses against NY-ESO-1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1.",

keywords = "Antibody response, CHP, Cancer vaccine, NY-ESO-1",

author = "Ryohei Kawabata and Hisashi Wada and Midori Isobe and Takashi Saika and Shuichiro Sato and Akiko Uenaka and Hiroshi Miyata and Takushi Yasuda and Yuichiro Doki and Yuji Noguchi and Hiromi Kumon and Kazuhide Tsuji and Keiji Iwatsuki and Hiroshi Shiku and Gerd Ritter and Roger Murphy and Eric Hoffman and Old, {Lloyd J.} and Morito Monden and Eiichi Nakayama",

year = "2007",

month = may,

day = "15",

doi = "10.1002/ijc.22583",

language = "English",

volume = "120",

pages = "2178--2184",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "10",

}

TY - JOUR

T1 - Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients

AU - Kawabata, Ryohei

AU - Wada, Hisashi

AU - Isobe, Midori

AU - Saika, Takashi

AU - Sato, Shuichiro

AU - Uenaka, Akiko

AU - Miyata, Hiroshi

AU - Yasuda, Takushi

AU - Doki, Yuichiro

AU - Noguchi, Yuji

AU - Kumon, Hiromi

AU - Tsuji, Kazuhide

AU - Iwatsuki, Keiji

AU - Shiku, Hiroshi

AU - Ritter, Gerd

AU - Murphy, Roger

AU - Hoffman, Eric

AU - Old, Lloyd J.

AU - Monden, Morito

AU - Nakayama, Eiichi

PY - 2007/5/15

Y1 - 2007/5/15

N2 - NY-ESO-1 specific humoral responses are frequently observed in patients with various types of NY-ESO-1 antigen expressing tumors. In a large proportion of NY-ESO-1 antibody-positive patients of NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring of the NY-ESO-1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY-ESO-1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY-ESO-1 protein formulated with cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) and investigated the humoral immune responses against NY-ESO-1. Seven patients were NY-ESO-1 antibody-negative and 2 patients were positive prior to vaccination. Vaccination with CHP-NY-ESO-1 resulted in the induction or increase of NY-ESO-1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY-ESO-1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY-ESO-1 antibody-positive cancer patients. A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients. In conclusion, we showed that CHP-NY-ESO-1 protein vaccination had a potent activity for inducing humoral immune responses against NY-ESO-1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1.

AB - NY-ESO-1 specific humoral responses are frequently observed in patients with various types of NY-ESO-1 antigen expressing tumors. In a large proportion of NY-ESO-1 antibody-positive patients of NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring of the NY-ESO-1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY-ESO-1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY-ESO-1 protein formulated with cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) and investigated the humoral immune responses against NY-ESO-1. Seven patients were NY-ESO-1 antibody-negative and 2 patients were positive prior to vaccination. Vaccination with CHP-NY-ESO-1 resulted in the induction or increase of NY-ESO-1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY-ESO-1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY-ESO-1 antibody-positive cancer patients. A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients. In conclusion, we showed that CHP-NY-ESO-1 protein vaccination had a potent activity for inducing humoral immune responses against NY-ESO-1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1.

KW - Antibody response

KW - CHP

KW - Cancer vaccine

KW - NY-ESO-1

UR - http://www.scopus.com/inward/record.url?scp=34147101570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147101570&partnerID=8YFLogxK

U2 - 10.1002/ijc.22583

DO - 10.1002/ijc.22583

M3 - Article

C2 - 17278093

AN - SCOPUS:34147101570

VL - 120

SP - 2178

EP - 2184

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -